Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
DepressionDepressive DisorderDepressive SymptomsDepressive Disorder, MajorDepressive EpisodeDepression Severe
Interventions
DRUG

TNX-601 ER

Patients will take 1 tablet orally once daily for 6 weeks.

DRUG

Placebo

Patients will take 1 tablet orally once daily for 6 weeks.

Trial Locations (27)

30030

Cenexel Research - Decatur, Decatur

30331

Cenexel ACMR - Atlanta, Atlanta

32256

Clinical Neuroscience Solutions - Jacksonville, Jacksonville

32801

Clinical Neuroscience Solutions - Orlando, Orlando

33016

Segal Trials - North Miami, Miami Lakes

33319

West Broward Outpatient Clinic, Lauderhill

33912

Gulfcoast Clinical Research Center, Fort Myers

38119

Clinical Neuroscience Solutions - Memphis, Memphis

60634

Chicago Research Center, Chicago

72211

Preferred Research Partners, Little Rock

75231

Futuresearch Trials of Dallas, Dallas

78737

Donald J. Garcia, Jr., Austin

80209

Mountain View Clinical Research, Denver

83704

Northwest Clinical Trials, Boise

90706

Cenexel CIT - Bellflower, Bellflower

91206

Behavioral Research Specialists, Glendale

91403

Cenexel CNR - Sherman Oaks, Sherman Oaks

91945

Synergy Research, Lemon Grove

92056

Excell Research, Oceanside

92103

Artemis Institute for Clinical Research, San Diego

92506

Cenexel CIT - Riverside, Riverside

92868

NCR Research Institute, Orange

92951

Viking Clinical Research, Temecula

97210

Summit Research Network, Portland

98201

Core Clinical Research, Everett

06416

CT Clinical Research Associates, Cromwell

08009

Cenexel HRI - Berlin, Berlin

All Listed Sponsors
collaborator

Rho, Inc.

INDUSTRY

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY